Metraipolis › archive › dc_89ecbcbe65b8

Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers — Europe PMC PMID:42138697

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42138697
DOI: 10.1128/aac.00268-26
License (as archived): solo-consultazione
Archived: 2026-11-02T07:44:48.409Z
SHA-256 of the archived text: fe69edaf0e3def11c8fa766b83a400816efa78cecebd20e12b23d42aa055ee95
Stable URL of this page: https://metraipolis.com/documento/dc_89ecbcbe65b8

How to cite

Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers — Europe PMC PMID:42138697 — Europe PMC (en), https://europepmc.org/article/MED/42138697 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_89ecbcbe65b8 (Metraipolis archive dc_89ecbcbe65b8, sha256 fe69edaf0e3def11c8fa766b83a400816efa78cecebd20e12b23d42aa055ee95)

BibTeX

@misc{dc89ecbcbe65b8,
  title = {Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers — Europe PMC PMID:42138697},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42138697},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_89ecbcbe65b8; sha256 fe69edaf0e3def11c8fa766b83a400816efa78cecebd20e12b23d42aa055ee95},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42138697. Agents can read the archived copy with the MCP tool read_document.